mcplogo color

Memorial Sloan Kettering Cancer Center, USA

The Mazumdar Shaw Translational Research Initiative in Kidney Cancer Research

Through its world class research enterprise and dedicated clinicians, Memorial Sloan Kettering Cancer Center (MSK) is leading the way in the detection and treatment of kidney cancer. MSK doctors and scientists take a personalised approach using targeted diagnostic methods, genetic sequencing of tumours, and innovative, tailored treatments to fight each patient’s cancer.

Mazumdar Shaw Philanthropy’s gift enabled the establishment of the Mazumdar Shaw Translational Research Initiative in Kidney Cancer Research in 2022. It has empowered four multidisciplinary teams of highly specialised physicians and scientists to make impressive strides toward innovative treatments that improve patient outcomes. Additionally, MSK has formalised their research goals into an application for a Specialized Programs of Research Excellence grant, a prestigious award of US$5 million given by the National Cancer Institute. This grant requires researchers to prove additional sources of funding, which MSP’s gift has supported. If approved, the grant will be used to establish a comprehensive translational kidney cancer research programme that will lay the foundation for a kidney cancer centre at MSK.

I am profoundly grateful to Kiran Mazumdar-Shaw for her generosity and vision to establish a translational research initiative for kidney cancer at MSK. Her gift has been a big boost to our research programs and will help us expand our decade-long work of leading global clinical studies with broad impact.

Robert Motzer, MD, Section Head of Kidney Cancer at the Genitourinary Oncology Service, and Jack and Dorothy Byrne Chair in Clinical Oncology

Research Focus

Play Video


Images courtesy: Memorial Sloan Kettering Cancer Center